Retrospective study to investigate the fluid balance in ovarian cancer surgery
Completed
- Conditions
- C56Malignant neoplasm of ovary
- Registration Number
- DRKS00033957
- Lead Sponsor
- niversitätsklinikum Bonn
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 73
Inclusion Criteria
cytoreductive tumour surgery
Exclusion Criteria
- final histology without evidence of ovarian carcinoma
- Anaesthesia protocol not available
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary endpoint is the intraoperative fluid balance. It was determined in litres at the end of each operation and expressed as the difference between fluid input and fluid output. The fluid input was calculated on the basis of the volume information on the infusion solutions and blood products supplied, while the fluid output was determined by measuring the volume.
- Secondary Outcome Measures
Name Time Method A secondary endpoint was the rate of postoperative complications that occurred during the postoperative stay. This information was taken (retrospectively) from the patient file.<br><br>Another secondary endpoint was the survival rate at 1 year and 5 years after surgery. As part of the clinical routine, all patients and their general practitioners were contacted (independent of the study) regularly every 6 months and asked about their condition (and survival). This information and any date of death were noted in the medical records (independently of the study). For the study, this information was taken from the patient file.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie fluid balance in ovarian cancer surgeries as studied in DRKS00033957?
How does fluid management in DRKS00033957 compare to standard-of-care practices for C56 malignancies?
Are there specific biomarkers associated with optimal fluid balance outcomes in DRKS00033957 ovarian cancer patients?
What adverse events are linked to fluid balance strategies in DRKS00033957 and how are they managed?
What are the implications of DRKS00033957 findings for combination therapies targeting C56 malignancies?